| Next 10 |
Ad
CLRB News and Press Cellectar Biosciences Inc.
News | Cellectar Biosciences Inc. (NASDAQ:CLRB)
-
FLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines...
-
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that it has closed on ...
-
2023-09-06 08:31:02 ET Verb Technology Company ( VERB ) -27% . Digital Brands Group ( DBGI ) -14% . GD Culture Group Limited ( GDC ) -12% . EZGO Technologies ( EZGO ) -10% . Photronics ( PLAB ) -9% after Q3 earning release . ...
-
2023-09-05 13:07:33 ET Gainers: Helius Medical Technologies ( HSDT ) +a55% . Novo Integrated Sciences ( NVOS ) +38% . Shengfeng Development Limited ( SFWL ) +29% . Cibus ( CBUS ) +28% . Cellectar Biosciences ( CLRB ) +28% . C...
-
2023-09-05 12:14:58 ET Cellectar Biosciences ( NASDAQ: CLRB ), a late-stage clinical biopharmaceutical company, Tuesday said it has entered into a securities purchase agreement with certain institutional investors for a private placement financing that is expected to result in gro...
-
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is one today's most active stocks by volume. So far today, approximately 29.61M shares of Cellectar Biosciences, Inc. have been exchanged, as compared to an average 30-day volume of 17,273 shares. Cellectar Biosciences, Inc., a clinical biopharmaceuti...
-
2023-09-05 10:00:14 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
-
Transaction led by existing investor Rosalind with participation from other new and existing healthcare-focused institutional investors Pivotal topline data in Waldenstrom’s macroglobulinemia expected in Q4 2023 with NDA submission and potential product launch in 2024 F...
-
2023-08-14 11:18:55 ET Cellectar Biosciences press release ( NASDAQ: CLRB ): Q2 GAAP EPS of -$0.73. As of June 30, 2023, the company had cash and cash equivalents of $5.2 million, compared to $19.9 million as of December 31, 2022. For further details see: Ce...
-
FLORHAM PARK, N.J., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted treatments for cancer, today announced financial results for the second quarter end...
Stock Information
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
Ad
-
FLORHAM PARK, N.J., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that the European Medicines...
-
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical comp...
-
FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced that it has closed on ...